Vertex Pharmaceuticals INC / Ma 8-K filings

Vertex Pharmaceuticals announced robust second quarter 2026 financial results, with total revenue up 12% to $3.33 billion, and raised its full-year revenue guidance.

Vertex Pharmaceuticals Incorporated held its annual meeting on May 13, 2026, where shareholders voted on key proposals including director elections and stock plan approvals.

Vertex Pharmaceuticals announced an 8% increase in first-quarter 2026 revenue to $2.99 billion, driven by strong performance in cystic fibrosis therapies and growth in new disease areas, while reiterating full-year financial guidance.

Vertex Pharmaceuticals has completed its Biologics Licensing Application submission to the FDA for povetacicept, seeking accelerated approval for immunoglobulin A nephropathy.

Vertex Pharmaceuticals announced robust fourth-quarter and full-year 2025 financial results, driven by CF therapies and new product launches, alongside optimistic 2026 revenue guidance and pipeline advancements.

Vertex Pharmaceuticals reported an 11% increase in Q3 2025 total revenue to $3.08 billion and refined its full-year financial guidance, driven by strong performance in CF therapies and new product launches.

Vertex Pharmaceuticals reported a 12% increase in second-quarter 2025 revenue to $2.96 billion, reiterated full-year guidance, and announced a planned Chief Scientific Officer transition.

Vertex Pharmaceuticals' board has authorized a new $4 billion stock repurchase program, adding to the existing authorization.

Vertex Pharmaceuticals held its annual shareholder meeting on May 14, 2025, and announced the results of voting on director elections, auditor ratification, executive compensation, and a shareholder proposal.

Vertex Pharmaceuticals announced a 3% increase in total revenue to $2.77 billion for Q1 2025 and raised the low end of its full-year revenue guidance by $100 million.

Vertex Pharmaceuticals discontinues the clinical development of VX-264 for type 1 diabetes and anticipates a $400 million non-cash impairment charge.

Vertex Pharmaceuticals announces positive financial results for 2024, driven by cystic fibrosis drug TRIKAFTA/KAFTRIO, and provides a promising revenue outlook for 2025, alongside strategic leadership changes.

The FDA has approved Vertex Pharmaceuticals' ALYFTREK for treating cystic fibrosis in patients 6 years and older with specific genetic mutations.

Vertex Pharmaceuticals reported a 12% increase in product revenue for the third quarter of 2024 and raised its full-year revenue guidance.

Vertex Pharmaceuticals has extended its headquarters leases in Boston to June 30, 2044, with options for further extensions.

Vertex Pharmaceuticals reported a 6% increase in product revenue for the second quarter of 2024 and raised its full-year revenue guidance.

Vertex Pharmaceuticals will record a one-time $4.4 billion expense related to its acquisition of Alpine Immune Sciences, impacting second quarter and full year 2024 financial results.

Vertex Pharmaceuticals has finalized its acquisition of Alpine Immune Sciences for approximately $5 billion, marking a significant expansion for the company.

Vertex Pharmaceuticals held its annual shareholder meeting on May 15, 2024, where directors were elected, the appointment of the auditor was ratified, executive compensation was approved, and other shareholder proposals were voted on.

Vertex Pharmaceuticals announced a 13% increase in product revenue for Q1 2024, reaching $2.69 billion, and reiterated its full-year financial guidance.

Vertex Pharmaceuticals has agreed to acquire Alpine Immune Sciences for $65 per share in cash, pending regulatory approvals and a successful tender offer.

Vertex Pharmaceuticals announced a strong 2023 with 11% revenue growth and provided a positive 2024 revenue guidance, alongside key regulatory approvals and pipeline advancements.